Skip to main content
. Author manuscript; available in PMC: 2008 Jun 11.
Published in final edited form as: Anesthesiology. 2008 May;108(5):882–887. doi: 10.1097/ALN.0b013e31816c8a8d

Fig. 2.

Fig. 2

Interaction of NMDA receptor NR2A/2B with PSD-95 in the spinal cord was disrupted by systemic administration with Tat-PSD-95 PDZ2. NR2A/2B antibody was used to immunoprecipitate NR2A/2B and its interacting proteins after intraperitoneal injection of Tat-PSD-95 PDZ2, mutated Tat-PSD-95 PDZ2 and PSD-95 PDZ2 without Tat. Note that Tat-PSD-95 PDZ2 (8 mg/kg) markedly blocked the interaction between NR2A/2B and PSD-95 and that mutated Tat-PSD-95 PDZ2 (8 mg/kg) had no effect on this interaction compared to the effect of PSD-95 PDZ2 (8 mg/kg). The amount of sample loaded for the input was 10% of that for the immunoprecipitation. The data shown are representative of three independent experiments (A) and the results after statistical analysis (B). *p < 0.05 vs. PSD-95 PDZ2 group. IP, immunoprecipitation; IB, immunoblotting.